Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

Key Points

• Hussman Strategic Advisors acquired a new stake of 8,400 shares in Amgen during Q4, valued at about $2.749 million.
• Amgen beat Q1 estimates with $5.15 EPS and $8.62B revenue, and set FY‑2026 EPS guidance of $21.70–$23.10 (consensus ~22.28), signaling largely in‑line but solid performance.
• Dividend announced: Amgen declared a $2.52 quarterly dividend ($10.08 annualized, ~3.1% yield), with an ex‑dividend date of May 15 and payment on June 5.

Hussman Strategic Advisors Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,400 shares of the medical research company's stock, valued at approximately $2,749,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Board of the Pension Protection Fund purchased a new position in Amgen in the fourth quarter valued at $26,000. Olistico Wealth LLC purchased a new position in Amgen in the fourth quarter valued at $33,000. Cloud Capital Management LLC purchased a new position in Amgen in the third quarter valued at $34,000. Ares Financial Consulting LLC purchased a new position in Amgen in the fourth quarter valued at $34,000. Finally, Saranac Partners Ltd purchased a new position in Amgen in the third quarter valued at $37,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

AMGN opened at $329.82 on Friday. The firm has a market capitalization of $178.00 billion, a PE ratio of 22.95, a PEG ratio of 3.26 and a beta of 0.44. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The firm's 50-day moving average price is $358.07 and its 200 day moving average price is $340.79. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. Amgen's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.28 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen's payout ratio is presently 70.84%.

Analyst Ratings Changes

A number of research firms have weighed in on AMGN. Jefferies Financial Group began coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a "hold" rating and a $350.00 price objective for the company. Citigroup lifted their price objective on shares of Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a research note on Thursday, February 5th. Sanford C. Bernstein cut shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 target price for the company. in a research note on Tuesday, January 20th. Finally, Guggenheim boosted their target price on shares of Amgen from $347.00 to $351.00 and gave the stock a "neutral" rating in a research note on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and an average price target of $357.54.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.